Geron Corporation reported $29M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $29M (to Q3 2024). Net income: −$68M, trailing twelve months to Q2 2026. EPS: −$0.11, trailing twelve months to Q2 2026. ROIC: −17%, trailing twelve months to Q2 2026.

GERNGeron Corporation

Healthcare

$1.21-6.2% 1Y

$1.21

$1.0752 weeks$1.95

GERN as reported

Geron Corporation reported $29M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

$29M

Revenue, trailing twelve months · to Q3 2024 · every figure below is as filed, with no scoring applied

Net income: −$68M
Net income · −23% year on year · trailing twelve months to Q2 2026
EPS: −$0.11
EPS · −15% year on year · trailing twelve months to Q2 2026
ROIC: −17%
ROIC · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for GERN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$29M	n/a	Q3 2024 · 7 quarters behind
Net income	−$68M	−23%	Q2 2026
EPS	−$0.11	−15%	Q2 2026
Operating margin	−65616%	n/a	Q3 2024 · 7 quarters behind
Net margin	−62981%	n/a	Q3 2024 · 7 quarters behind
ROE	−32%	n/a	Q2 2026
ROA	−14%	n/a	Q2 2026
ROIC	−17%	n/a	Q2 2026
Free cash flow	−$220M	n/a	Q4 2024 · 6 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.